Home · Guides · Healthcare M&A NJ
Healthcare M&A · NJ · NY · CT
A working healthcare M&A broker's guide to selling NJ and NY medical practices, dental practices, behavioral health programs, pharmacies, urgent care centers, and outpatient diagnostic & treatment centers. Covers Article 28, Article 31 / MHOTRS, MSO/CPOM structures, Stark/Anti-Kickback considerations, PE buyer landscape, and 2026 valuation multiples.
Selling a healthcare practice in New Jersey or New York is not selling a business in the conventional sense. Healthcare M&A sits inside a layered regulatory framework that touches almost every transaction structure: Corporate Practice of Medicine (CPOM) doctrine prohibits non-physician ownership of medical practices; the NJ Board of Medical Examiners and NY State Department of Health govern licensure transitions; Article 28 of NY Public Health Law requires Certificate of Need approvals for diagnostic and treatment centers; Article 31 of NY Mental Hygiene Law (and its MHOTRS implementation) governs outpatient mental health programs; the Stark Law and Anti-Kickback Statute (AKS) shape compensation structures and referral relationships; HIPAA defines data-handover requirements; Medicare PECOS and Medicaid eMedNY require re-enrollment for ownership changes.
An M&A advisor without specific healthcare experience can structure a deal that violates one or more of these regimes — sometimes years after close, with retroactive penalties. The right healthcare M&A broker pre-screens each issue during listing prep, structures the deal to comply, and coordinates with healthcare regulatory counsel from LOI through closing.
Nexus Bridge Business Brokers operates a dedicated healthcare M&A practice serving NJ, NY, NYC, and CT. We've closed deals across medical practices (primary care, specialty), dental practices, behavioral health (Article 31 / MHOTRS), pharmacy, urgent care, and outpatient diagnostic & treatment centers in the $500K–$15M range. This page describes how we approach each major healthcare deal type.
NJ medical practices typically sell for 4×–7× trailing-12 EBITDA, with significant variation by specialty, payer mix, and buyer type. The PE-driven roll-up activity that compressed primary care multiples in 2022–2024 has stabilized; specialty practices remain at premium multiples.
| Specialty | Typical NJ Multiple (2026) | Drivers of premium |
|---|---|---|
| Primary care / FM | 3×–5× EBITDA | Value-based care contracts, Medicare Advantage panel |
| Cardiology | 5×–8× EBITDA | Ancillaries (echo, stress testing), PE platform interest |
| Orthopedics | 5×–8× EBITDA | Surgery center ownership, MSK service line |
| Ophthalmology | 6×–9× EBITDA | ASC participation, premium IOL volume |
| Dermatology | 6×–10× EBITDA | Cosmetic mix, PE platform interest very high |
| Gastroenterology | 5×–8× EBITDA | Endoscopy ASC ownership |
| Pain management | 3×–5× EBITDA | Regulatory risk, payer scrutiny |
| Behavioral health (outpatient) | 5×–9× EBITDA | Article 31 / MHOTRS licensure, recurring caseload |
| Urgent care | 4×–7× EBITDA | Site density, payer contracts |
| Independent pharmacy | 3×–5× EBITDA + script file | Specialty mix, DIR exposure |
Three valuation drivers consistently matter more than specialty alone: (1) physician retention — will the selling physician(s) stay 2–3 years post-close at agreed comp? (2) payer contract assignability — can the buyer carry over fee schedules, or do contracts need re-negotiation? (3) EHR transition risk — can the buyer migrate or maintain the existing EHR without revenue disruption? Practices that pre-solve all three command top-of-range multiples.
NJ and NY both enforce the Corporate Practice of Medicine (CPOM) doctrine: only licensed physicians may own a medical practice. Non-physician investors — including PE firms, family offices, and most strategic buyers — cannot directly own a NJ medical practice. The workaround is the MSO (Management Services Organization) / Friendly-PC structure: the clinical practice (PC or PLLC) remains owned by licensed physicians, while a separate management entity (LLC, owned by the PE firm or investor) provides admin services, IT, billing, real estate, HR, and management for a fee.
The MSO/Friendly-PC structure is the dominant deal structure for PE-backed acquisitions of NJ medical and dental practices. Done correctly, it complies with CPOM while routing 80%+ of practice economics to the investor through service-fee arrangements. Done incorrectly, it violates CPOM and creates retroactive corporate-practice exposure.
Three structural choices materially affect outcomes:
For sellers who plan to stay 2–3 years post-close, MSO/Friendly-PC structures are standard and well-understood. For sellers planning a clean exit at close, asset-only sales to physician-buyers remain the cleanest path.
NY Article 28 of the Public Health Law governs diagnostic and treatment centers (D&TCs) — outpatient clinics, ambulatory surgery centers, and similar facilities. Any change in 10%+ ownership of an Article 28 facility requires NY Department of Health (DOH) approval through the Public Health and Health Planning Council (PHHPC), commonly known as the Certificate of Need (CON) process.
CON approvals typically take 6–12 months from filing. The state evaluates: financial capability of the buyer, character/competence of the principals, community need, and quality-of-care implications. Filings include audited financials, organizational charts, governance documents, and operational continuity plans.
For Article 28 sellers, two transaction structures preserve continuity during the CON wait:
Article 28 transactions also frequently involve Medicaid Managed Care provider transitions and CMS PECOS re-enrollments. Plan for parallel regulatory workstreams — PHHPC, DOH licensure, CMS, Medicaid Managed Care, and commercial payer credentialing.
NY Article 31 of the Mental Hygiene Law (implemented in 2023 as Mental Health Outpatient Treatment and Rehabilitative Services — MHOTRS) governs outpatient mental health programs. Like Article 28, Article 31 facilities require NY Office of Mental Health (OMH) approval for ownership changes.
OMH approvals take 4–9 months and are typically less complex than PHHPC CONs because OMH focuses primarily on operator character, financial capacity, and program-quality continuity. The substantive review is faster than Article 28 D&TC.
The growth of MHOTRS programs and the move toward Collaborative Care and integrated primary care + behavioral health has produced active PE buyer interest in NJ/NY behavioral health practices — particularly multi-site OMH-licensed Article 31 programs with $1M+ EBITDA. Valuation multiples in 2026 range from 6× to 10× EBITDA, with the upper end reserved for PE-attractive scale.
NJ independent pharmacies typically sell for a combination of business multiple (3×–5× EBITDA) plus standalone prescription-file value (variable based on script count, payer mix, and specialty exposure). DIR fees, PBM contract renewals, and immunization/clinical revenue diversification are the primary 2026 valuation drivers.
Buyer types vary: chain consolidators (CVS, Walgreens, Rite Aid — though much-reduced activity in 2026), independent operators expanding regionally, specialty pharmacy platforms, and 340B-eligible covered entity acquirers. Each buyer type values different aspects of the practice — chains pay for prescription file alone, independents pay for the whole operation, specialty platforms pay for therapeutic class concentration.
NJ pharmacy permit transfers (via NJ Division of Consumer Affairs and the Board of Pharmacy) require buyer Pharmacist-in-Charge designation and facility re-inspection. Timeline: 3–6 months. Asset-only sales avoid permit transfer through closing the existing entity and opening under new permits, but with operational gap and prescription file revaluation.
Dental M&A in NJ has been the most active healthcare segment in 2024–2026, driven by Dental Service Organization (DSO) consolidation. Active NJ-targeting DSOs include Heartland Dental, Smile Brands, Dental Care Alliance, Pacific Dental Services, Mid-Atlantic Dental Partners, and a growing roster of regional DSOs.
NJ general dental practices typically sell for 65%–85% of trailing-12 collections, or 4×–6× EBITDA. Specialty dental (orthodontics, periodontics, oral surgery, endodontics, pediatric dentistry) commands 5×–8× EBITDA, with implant-heavy and cosmetic-heavy practices at the high end.
The standard DSO acquisition structure follows MSO/Friendly-PC mechanics adapted for dental: the DSO acquires a management entity that contracts to provide services to the dental PC; the selling dentist often rolls 20–30% of equity into the DSO platform for upside participation, with the remaining 70–80% paid in cash at close. Most DSO deals require seller-dentist continuity 2–3 years post-close at agreed comp (typically 28–32% of personal collections).
PE activity in NJ healthcare M&A remains strong despite higher interest rates. Sub-segments with active 2026 buyer interest:
For sellers targeting PE buyers, the engagement letter, financial preparation, and quality-of-earnings (QoE) workstream materially affect outcomes. PE buyers expect normalized EBITDA, GAAP-compliant accounting, and reproducible recurring-revenue analysis. Investing $20K–$40K in pre-listing QoE typically returns $200K–$2M in valuation pickup.
If you're considering a NJ/NY/CT healthcare M&A transaction in the next 6–36 months, the highest-value first step is a free, confidential 30-minute conversation to scope the engagement and produce an evidence-based valuation range. Nexus Bridge charges $0 upfront, success-only commission, and zero obligation through the discovery phase.
Related: Sell a Medical Practice in NJ · Sell a Dental Practice in NJ · Sell Your Outpatient Clinic · Sell a NJ Pharmacy · NJ Pharmacy Sale Report 2026